Funded Startups in La Jolla
Among the 33 La Jolla–based funded startups shown (sorted by round date descending), Janux Therapeutics’ $350M (2024-12-03) is a major outlier in disclosed…
Among the 33 La Jolla–based funded startups shown (sorted by round date descending), Janux Therapeutics’ $350M (2024-12-03) is a major outlier in disclosed funding: it sits far above the next-largest disclosed rounds such as NeoVolta’s $250M (2024-11-13) and Inhibrx’s $150M (2025-01-13), while many other entries cluster well below $100M (for example, AeroRx Therapeutics $21M on 2025-10-08 and Enlaza Therapeutics $15M on 2025-09-13). Funding activity concentrates in a biotech-heavy mix across a long temporal span, with rounds in the dataset ranging from 2020-09-21 (Dare Bioscience, $900K) through the most recent 2025-11-15 (Fabric8Labs, $50M).
Two additional patterns stand out: multiple rounds cluster in the 2024–2025 window (e.g., Janux 2024-12-03, NeoVolta 2024-11-13, Kura Oncology 2024-01-24, and Equillium 2025-08-11), and biotech categories dominate repeat appearances (Biotechnology appears in far more than 3 entries, including Inhibrx 2025-01-13 $150M; Kura Oncology 2024-01-24 $150M; and Genome Insight 2023-11-01 $23M). The list also includes several rounds with unavailable or unspecified amounts/classifications: “undisclosed” appears alongside AlphaCore (2023-12-05) and Tentarix Biotherapeutics (2023-08-15), while “Series Unknown” appears frequently across both biotech and non-biotech entries (such as Events.com, $100M on 2024-09-12).
Most recent rounds
33 shownRelated listings
Frequently asked
What’s the largest disclosed round among the La Jolla entries, and how separated is it from the rest?
Janux Therapeutics’ $350M (2024-12-03) is the top disclosed amount in the table and clearly dwarfs the next-largest disclosed rounds, including NeoVolta’s $250M (2024-11-13) and Inhibrx’s $150M (2025-01-13). Most other disclosed rounds fall below $100M, such as AeroRx Therapeutics $21M (2025-10-08) and CalciMedica $10M (2025-03-05).
Do the rounds cluster tightly in time near the most recent months?
Yes, the dataset shows multiple 2025 closings near the top of the list: Fabric8Labs $50M (2025-11-15), AeroRx Therapeutics $21M (2025-10-08), Enlaza Therapeutics $15M (2025-09-13), and Equillium $30M (2025-08-11). Over longer reading windows, entries also recur throughout 2024 (e.g., NeoVolta $250M on 2024-11-13 and Kura Oncology $150M on 2024-01-24), indicating sustained rather than single-spike activity.
Which sectors appear most often, and are they driving the disclosed-dollar concentration?
Biotechnology appears in far more than 3 entries, including Janux Therapeutics $350M (2024-12-03), Inhibrx $150M (2025-01-13), and Boundless Bio $100M (2023-05-16). Those largest disclosed rounds are all biotech-linked in the table’s top end (e.g., Janux $350M, NeoVolta $250M as consumer electronics, and Inhibrx $150M), while several non-biotech categories show smaller disclosed amounts like Comparative Cognition Lab $200K (2024-10-15) and XNow $530K (2023-01-19).
How much of the list has missing or non-disclosed funding or stage labels, and does that affect comparisons?
Two entries show “undisclosed” amounts: AlphaCore (2023-12-05) and Tentarix Biotherapeutics (2023-08-15), so they can’t be used for largest/smallest comparisons by dollars. Separately, “Series Unknown” appears repeatedly (for example, Equillium $30M on 2025-08-11 and Events.com $100M on 2024-09-12), meaning stage-level patterning from labels will be incomplete even when amounts are disclosed.
Are there notable low-end outliers in disclosed funding compared with the rest of the list?
The smallest disclosed amount shown is $200K for Comparative Cognition Lab (2024-10-15), which sits well below many other disclosed rounds such as JackRabbit Mobility $500K (2021-02-11), Learning Equality $500K (2023-12-20), and XNow $530K (2023-01-19). Even among the lower half, most disclosed amounts remain in the hundreds of thousands to tens of millions range, making $200K a clear bottom outlier.
What stage mix dominates the La Jolla list once rounds with known dollar amounts are considered?
Known-stage labels appear across multiple rounds, including Series A (AeroRx Therapeutics $21M on 2025-10-08; Rampart Bioscience $85M on 2023-10-24), Series B (Genome Insight $23M on 2023-11-01; PetDx $62M on 2021-12-09), and higher-letter series (Epic Sciences Series G $24M on 2023-04-14; Boundless Bio Series C $100M on 2023-05-16). However, “Series Unknown” is common (including Inhibrx $150M on 2025-01-13 and Equillium $30M on 2025-08-11), which limits confident stage-frequency conclusions.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.